Fintel reports that on February 10, 2025, HC Wainwright & Co. downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX ...

H.C. Wainwright analyst Andrew Fein adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $185 from the previous $190 while maintaining a Buy rating on the stock. This revision follows ...

HC Wainwright restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a report released on ...

H.C. Wainwright downgraded Pliant Therapeutics (PLRX) to Neutral from Buy without a price target after the company voluntarily paused ...

HC Wainwright reissued their buy rating on shares of Genfit (NASDAQ:GNFT – Free Report) in a report published on Friday,Benzinga reports. HC Wainwright currently has a $13.00 price target on the stock ...

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...